195 related articles for article (PubMed ID: 12556199)
1. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
2. Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.
Peng Y; Keenan SM; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):72-80. PubMed ID: 16046158
[TBL] [Abstract][Full Text] [Related]
3. Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases.
Li Z; Le Roch K; Geyer JA; Woodard CL; Prigge ST; Koh J; Doerig C; Waters NC
Biochem Biophys Res Commun; 2001 Nov; 288(5):1207-11. PubMed ID: 11700040
[TBL] [Abstract][Full Text] [Related]
4. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
Woodard CL; Li Z; Kathcart AK; Terrell J; Gerena L; Lopez-Sanchez M; Kyle DE; Bhattacharjee AK; Nichols DA; Ellis W; Prigge ST; Geyer JA; Waters NC
J Med Chem; 2003 Aug; 46(18):3877-82. PubMed ID: 12930149
[TBL] [Abstract][Full Text] [Related]
5. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
6. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum.
Waters NC; Woodard CL; Prigge ST
Mol Biochem Parasitol; 2000 Mar; 107(1):45-55. PubMed ID: 10717301
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
8. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
9. In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.
Eubanks AL; Perkins MM; Sylvester K; Ganley JG; Posfai D; Sanschargrin PC; Hong J; Sliz P; Derbyshire ER
ChemMedChem; 2018 Dec; 13(23):2479-2483. PubMed ID: 30328274
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
11. Molecular models of protein kinase 6 from Plasmodium falciparum.
Manhani KK; Arcuri HA; da Silveira NJ; Uchôa HB; de Azevedo WF; Canduri F
J Mol Model; 2005 Dec; 12(1):42-8. PubMed ID: 16096806
[TBL] [Abstract][Full Text] [Related]
12. The Malaria Parasite Cyclin H Homolog PfCyc1 Is Required for Efficient Cytokinesis in Blood-Stage
Robbins JA; Absalon S; Streva VA; Dvorin JD
mBio; 2017 Jun; 8(3):. PubMed ID: 28611247
[TBL] [Abstract][Full Text] [Related]
13. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors.
Keenan SM; Geyer JA; Welsh WJ; Prigge ST; Waters NC
Comb Chem High Throughput Screen; 2005 Feb; 8(1):27-38. PubMed ID: 15720195
[TBL] [Abstract][Full Text] [Related]
14. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue.
Le Roch K; Sestier C; Dorin D; Waters N; Kappes B; Chakrabarti D; Meijer L; Doerig C
J Biol Chem; 2000 Mar; 275(12):8952-8. PubMed ID: 10722743
[TBL] [Abstract][Full Text] [Related]
15. Plasmodium kinases as targets for new-generation antimalarials.
Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
[TBL] [Abstract][Full Text] [Related]
16. Why is the Plasmodium falciparum hexose transporter a promising new drug target?
Joët T; Morin C; Fischbarg J; Louw AI; Eckstein-Ludwig U; Woodrow C; Krishna S
Expert Opin Ther Targets; 2003 Oct; 7(5):593-602. PubMed ID: 14498822
[TBL] [Abstract][Full Text] [Related]
17. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.
Li JL; Robson KJ; Chen JL; Targett GA; Baker DA
Eur J Biochem; 1996 Nov; 241(3):805-13. PubMed ID: 8944769
[TBL] [Abstract][Full Text] [Related]
18. Correlation between Cyclin Dependent Kinases and Artemisinin-Induced Dormancy in Plasmodium falciparum In Vitro.
Gray KA; Gresty KJ; Chen N; Zhang V; Gutteridge CE; Peatey CL; Chavchich M; Waters NC; Cheng Q
PLoS One; 2016; 11(6):e0157906. PubMed ID: 27326764
[TBL] [Abstract][Full Text] [Related]
19. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
20. PfPK6, a novel cyclin-dependent kinase/mitogen-activated protein kinase-related protein kinase from Plasmodium falciparum.
Bracchi-Ricard V; Barik S; Delvecchio C; Doerig C; Chakrabarti R; Chakrabarti D
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):255-63. PubMed ID: 10727426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
